Brigatinib

136 interactions 323 cited references
Also sold as: Alunbrig Alunbrig®
About Brigatinib

Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys. Brigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread… Read the full Brigatinib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Major

Brigatinib Abametapir Increased exposure of CYP3A4 substrate Details Brigatinib Relugolix Orgovyx Increased relugolix exposure Details Brigatinib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Brigatinib Atogepant Qulipta Reduced atogepant exposure Details Brigatinib Cariprazine Vraylar Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Brigatinib Amlodipine Amvaz® Reduced amLODIPine exposure Details Brigatinib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Brigatinib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Brigatinib Alfentanil Reduced ALfentanil exposure, reduced efficacy of ALfentanil and an increased risk of a withdrawal syndrome Details Brigatinib Apalutamide Erleada Reduced brigatinib efficacy Details Brigatinib Aprepitant Aponvie Increased brigatinib exposure Details Brigatinib Artemether Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Brigatinib Atazanavir Reyataz Increased brigatinib exposure Details Brigatinib Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Brigatinib Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Brigatinib Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Brigatinib Boceprevir Increased brigatinib exposure Details Brigatinib Bosentan Decreased brigatinib exposure and efficacy Details Brigatinib Carbamazepine Carbatrol Reduced brigatinib efficacy Details Brigatinib Ceritinib Zykadia Increased exposure of CYP3A substrate Details Brigatinib Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Brigatinib Ciprofloxacin Increased brigatinib exposure Details Brigatinib Clarithromycin Biaxin Increased brigatinib exposure Details Brigatinib Cobicistat Tybost Increased brigatinib exposure Details Brigatinib Conivaptan Vaprisol Increased brigatinib exposure Details Brigatinib Crizotinib Xalkori Increased brigatinib exposure Details Brigatinib Cyclosporine Atopica Increased brigatinib exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.